Last reviewed · How we verify
Ritonavir boosted Atazanavir + Lamivudine
Ritonavir boosted Atazanavir + Lamivudine is a Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitor) Small molecule drug developed by Fundacion SEIMC-GESIDA. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients.
This combination inhibits HIV protease and reverse transcriptase to block viral replication, with ritonavir boosting atazanavir levels through CYP3A4 inhibition.
This combination inhibits HIV protease and reverse transcriptase to block viral replication, with ritonavir boosting atazanavir levels through CYP3A4 inhibition. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Ritonavir boosted Atazanavir + Lamivudine |
|---|---|
| Sponsor | Fundacion SEIMC-GESIDA |
| Drug class | Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitor) |
| Target | HIV protease; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins necessary for infectious particle formation. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that terminates HIV RNA chain elongation. Ritonavir, a potent CYP3A4 inhibitor, is used at sub-therapeutic doses to increase atazanavir plasma concentrations, allowing for lower atazanavir dosing and improved tolerability.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Hyperbilirubinemia
- Nausea
- Diarrhea
- Headache
- Rash
- Abdominal pain
- Nephrolithiasis
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia (NA)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (PHASE3)
- ANRS 12372 MODERATO Study (PHASE3)
- Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ritonavir boosted Atazanavir + Lamivudine CI brief — competitive landscape report
- Ritonavir boosted Atazanavir + Lamivudine updates RSS · CI watch RSS
- Fundacion SEIMC-GESIDA portfolio CI
Frequently asked questions about Ritonavir boosted Atazanavir + Lamivudine
What is Ritonavir boosted Atazanavir + Lamivudine?
How does Ritonavir boosted Atazanavir + Lamivudine work?
What is Ritonavir boosted Atazanavir + Lamivudine used for?
Who makes Ritonavir boosted Atazanavir + Lamivudine?
What drug class is Ritonavir boosted Atazanavir + Lamivudine in?
What development phase is Ritonavir boosted Atazanavir + Lamivudine in?
What are the side effects of Ritonavir boosted Atazanavir + Lamivudine?
What does Ritonavir boosted Atazanavir + Lamivudine target?
Related
- Drug class: All Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitor) drugs
- Target: All drugs targeting HIV protease; HIV reverse transcriptase
- Manufacturer: Fundacion SEIMC-GESIDA — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Compare: Ritonavir boosted Atazanavir + Lamivudine vs similar drugs
- Pricing: Ritonavir boosted Atazanavir + Lamivudine cost, discount & access